The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
Sale, Matthew J., Cook, Simon J.Volume:
450
Language:
english
Journal:
Biochemical Journal
DOI:
10.1042/BJ20121212
Date:
March, 2013
File:
PDF, 921 KB
english, 2013